Advertisement

Navigating Giant Cell Arteritis: Diagnosis, Management, and the Road Ahead - Episode 16

Experts Discuss the REPLENISH Trial for Polymyalgia Rheumatica

Published on: 
, , ,
EP. 1: An Overview of Giant Cell Arteritis (GCA): Common Signs and Symptoms
EP. 2: The Underlying Causes of GCA: Environmental and Genetic Factors
EP. 3: Current Gaps in Diagnostic Criteria Standards: Key Factors That Inform Diagnostic Decisions
EP. 4: Non-Cranial Symptoms in GCA
EP. 5: Imaging Modalities for Diagnosing GCA: What Clinicians are Doing in Clinic
EP. 6: Discussing the Overlap of Polymyalgia Rheumatica in Patients With GCA
EP. 7: Diagnostic Blood Testing in GCA
EP. 8: Expert Perspectives on the Reasons for Diagnostic Delay in GCA
EP. 9: The Physical and Mental Quality of Life Impacts of GCA
EP. 10: Current Standards of Care in GCA Treatment
EP. 11: Real-World Complications Using Steroids to Treat GCA
EP. 12: Current Pathway Treatment Targets in GCA
EP. 13: Reflecting on the Trial Landscape in GCA and History of Approved Agents
EP. 14: Clinical Experience with Tocilizumab and Upadacitinib in GCA Treatment
EP. 15: The Trial Design and Interim Results From the GCAptAIN Trial
Now Viewing
EP. 16: Experts Discuss the REPLENISH Trial for Polymyalgia Rheumatica

This video covers the following questions:

  1. Secukinumab is also being investigated as treatment for PMR in the REPLENISH-EXT trial. Please share your perspectives on this trial and the impact it may have on the treatment landscape.
Advertisement
Advertisement